ImmuCell Announces Selection of its Next President and CEO
ImmuCell Corporation (Nasdaq: ICCC) has announced the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, currently an Operating Partner at ARCHIMED and Chair of SeqCenter's Board, brings extensive industry experience from his 18-year tenure at IDEXX Laboratories, where he led significant growth initiatives in livestock diagnostics.
The transition includes current President and CEO Michael F. Brigham serving as Special Advisor for at least two months, while maintaining his Board position. Te Boekhorst's compensation package includes two stock option grants - an initial 76,673 shares at $5.90 per share and a subsequent grant of up to 85,000 shares, both vesting over three years.
ImmuCell Corporation (Nasdaq: ICCC) ha annunciato la nomina di Olivier te Boekhorst come nuovo presidente e CEO, con effetto dal 1 novembre 2025. Te Boekhorst, attualmente Operating Partner presso ARCHIMED e presidente del consiglio di SeqCenter, porta una vasta esperienza nel settore maturata durante i 18 anni trascorsi in IDEXX Laboratories, dove ha guidato significativi progetti di crescita nella diagnostica per il bestiame.
La transizione prevede che l'attuale presidente e CEO Michael F. Brigham ricopra il ruolo di Special Advisor per almeno due mesi, mantenendo anche la sua carica nel Consiglio. Il pacchetto retributivo di Te Boekhorst comprende due concessioni di stock option - una prima di 76.673 azioni a 5,90 USD per azione e una successiva concessione di fino a 85.000 azioni, entrambe con maturazione su tre anni.
ImmuCell Corporation (Nasdaq: ICCC) anunció el nombramiento de Olivier te Boekhorst como su nuevo presidente y director ejecutivo, con efecto a partir del 1 de noviembre de 2025. Te Boekhorst, actualmente socio operativo en ARCHIMED y presidente de la junta de SeqCenter, aporta amplia experiencia de la industria tras 18 años en IDEXX Laboratories, donde dirigió iniciativas de crecimiento significativas en el diagnóstico de ganado.
La transición incluye que el actual presidente y director ejecutivo Michael F. Brigham se desempeñe como asesor especial durante al menos dos meses, manteniendo su cargo en la Junta. El paquete de compensación de Te Boekhorst incluye dos concesiones de opciones sobre acciones - primero 76.673 acciones a 5,90 USD por acción y una concesión posterior de hasta 85.000 acciones, ambas con vesting durante tres años.
ImmuCell Corporation (Nasdaq: ICCC)는 새로운 사장 겸 최고경영자(CEO)로 Olivier te Boekhorst를 임명했다고 발표했습니다. 임기는 2025년 11월 1일부터입니다. Te Boekhorst는 현재 ARCHIMED의 운영 파트너이며 SeqCenter 이사회 의장을 맡고 있으며, IDEXX Laboratories에서 18년간 축산 진단 분야의 성장 이니셔티브를 이끈 광범위한 산업 경력을 보유하고 있습니다.
전환에는 현재의 사장 겸 CEO인 Michael F. Brigham이 최소 두 달 동안 특별 자문으로 근무하고 이사회 의석을 유지하는 것이 포함됩니다. Te Boekhorst의 보상 패키지는 두 차례의 주식 옵션 부여를 포함합니다. 처음 76,673주를 주당 5.90달러로, 그리고 이후 최대 85,000주를 부여하며, 둘 다 3년간 vesting됩니다.
ImmuCell Corporation (Nasdaq: ICCC) a annoncé la nomination de Olivier te Boekhorst au poste de nouveau président et directeur général, à compter du 1er novembre 2025. Te Boekhorst, actuellement partenaire opérationnel chez ARCHIMED et président du conseil de SeqCenter, apporte une vaste expérience de l'industrie acquise au cours de ses 18 années chez IDEXX Laboratories, où il a dirigé des initiatives de forte croissance dans le domaine du diagnostic pour le bétail.
La transition prévoit que l'actuel président et CEO Michael F. Brigham occupe le rôle de conseiller spécial pendant au moins deux mois, tout en conservant son siège au conseil. Le paquet de rémunération de Te Boekhorst comprend deux attributions d'options d'actions — une première de 76 673 actions à 5,90 dollars l'action et une attribution subséquente pouvant atteindre 85 000 actions, les deux vesting sur trois ans.
ImmuCell Corporation (Nasdaq: ICCC) hat die Ernennung von Olivier te Boekhorst zum neuen Präsidenten und CEO bekannt gegeben, wirksam ab dem 1. November 2025. Te Boekhorst ist derzeit Operating Partner bei ARCHIMED und Vorsitzender des SeqCenter-Vorstands und bringt umfassende Branchenerfahrung aus seiner 18-jährigen Tätigkeit bei IDEXX Laboratories mit, wo er bedeutende Wachstumsinitiativen in der Tierdiagnostik leitete.
Im Übergang wird der derzeitige Präsident und CEO Michael F. Brigham mindestens zwei Monate als Sonderberater fungieren, während er seinen Sitz im Vorstand behält. Te Boekhorsts Vergütungspaket umfasst zwei Aktienoptionszuteilungen – eine initiale über 76.673 Aktien zu 5,90 USD je Aktie und eine anschließende Zuteilung von bis zu 85.000 Aktien, welche beide über drei Jahre vesten.
أعلنت ImmuCell Corporation (نازداك: ICCC) عن تعيين Olivier te Boekhorst كالرئيس التنفيذي الجديد، اعتباراً من 1 نوفمبر 2025. يأتي Boekhorst وهو حالياً شريك تشغيلي في ARCHIMED ورئيس مجلس SeqCenter بخبرة صناعية واسعة من فترة امتدت 18 عاماً في IDEXX Laboratories، حيث قاد مبادرات نمو كبيرة في تشخيص المواشي.
تشمل الفترة الانتقالية أن يعمل الرئيس التنفيذي الحالي مايكل ف. بريغهام كمستشار خاص لمدة لا تقل عن شهرين، مع الحفاظ على مقعده في المجلس. وتشتمل حزمة تعويض Te Boekhorst على منحين لخيارات الأسهم — الأول 76,673 سهماً بسعر 5.90 دولار للسهم، والمنح اللاحقة حتى 85,000 سهم، وكلاهما يخضع للالتزام خلال ثلاث سنوات.
ImmuCell Corporation (纳斯达克：ICCC)宣布任命 Olivier te Boekhorst为公司新任总裁兼首席执行官，生效日期为 2025 年 11 月 1 日。Te Boekhorst 目前为 ARCHIMED 的运营合伙人并担任 SeqCenter 董事会主席，具备在 IDEXX Laboratories 长达 18 年的业界经验，在畜牧诊断领域推动了显著的增长计划。
过渡阶段包括现任总裁兼首席执行官 Michael F. Brigham 担任至少两个月的特别顾问，同时保留其董事会席位。Te Boekhorst 的薪酬方案包括两次股票期权授予——首次 76,673 股，行权价 5.90 美元/股，随后再授予最高 85,000 股，两者均在三年内归属。
- Appointment of experienced industry executive with strong background in animal health and diagnostics
- Structured leadership transition plan with current CEO staying as advisor
- New CEO brings valuable M&A and growth experience from IDEXX Laboratories
- Alignment with shareholders through significant equity compensation package
- Potential dilution from significant stock option grants to new CEO
- Risk of leadership transition disrupting current business momentum
Insights
ImmuCell's new CEO brings industry experience from IDEXX that could strengthen product growth opportunities for First Defense and Re-Tain.
ImmuCell's selection of Olivier te Boekhorst as its next President and CEO represents a significant leadership transition for the animal health company. Te Boekhorst's background is particularly relevant to ImmuCell's growth trajectory—his extensive experience at IDEXX Laboratories from 2004-2022 included leading livestock and dairy diagnostics divisions, which aligns perfectly with ImmuCell's market focus.
The timing of this transition appears strategic. The press release notes that ImmuCell has successfully established increased production capacity for its First Defense® product line, which provides immediate immunity to newborn calves. The company is also progressing with Re-Tain®, its novel treatment for subclinical mastitis that offers an antibiotic-free approach. Both products address key needs in dairy and beef cattle health management.
The compensation structure for te Boekhorst includes significant equity incentives, with stock options for up to
The orderly transition plan, with outgoing CEO Brigham serving as Special Advisor and continuing on the Board of Directors, suggests continuity in corporate strategy while bringing in fresh leadership perspective. Te Boekhorst's M&A experience at IDEXX could potentially signal future growth opportunities beyond organic expansion for ImmuCell's antibiotic-alternative products in the animal health market.
PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst.
Mr. te Boekhorst is currently an Operating Partner at ARCHIMED, a global investment firm focused on human and animal healthcare industries, and serves as Chair of the Board of SeqCenter, a Next Generation Sequencing laboratory located in Pittsburgh, PA, where he previously served as CEO. From 2004 to 2022, he held several leadership roles at Maine-based global diagnostics leader IDEXX Laboratories. At IDEXX, Mr. te Boekhorst led M&A activities consolidating the livestock diagnostics segment, and as Senior VP he grew the livestock and dairy diagnostics, water safety testing, and human diagnostics divisions. He launched and grew multiple innovations for dairy and beef producers worldwide to drive customer and shareholder value. Early in his career, Mr. te Boekhorst worked for the Boston Consulting Group and received an MBA from Cornell University.
“Change is good, and handing off leadership to Olivier at this time is an exciting next step for the Company,” said Michael F. Brigham, the Company’s current President and CEO. “Olivier brings to the Company a depth of experience and industry contacts that we expect will be very valuable as we work to grow First Defense® sales with our increased production capacity now successfully in place, and progress next steps for Re-Tain®.”
“I am excited to join the ImmuCell organization as President and CEO at this pivotal time, with exciting opportunities for First Defense® and Re-Tain® ahead of us,” commented Mr. te Boekhorst. “ImmuCell has a unique opportunity to improve farm animal welfare and contribute to the sustainability of the dairy and beef industries by offering solutions that address scours and mastitis without traditional antibiotics. I am impressed with the ImmuCell team, and I look forward to working with them to create value for customers and stockholders.”
After Mr. te Boekhorst’s start date, Mr. Brigham will serve as Special Advisor to the CEO for at least two months, to help assure a smooth transition. Mr. Brigham also will continue to serve on the Company’s Board of Directors until the next Annual Meeting of Stockholders and looks forward to continued Board service thereafter subject to re-election by stockholders.
The terms of Mr. te Boekhorst’s employment include two initial awards of stock options as inducement grants under terms approved by Company’s Compensation and Stock Option Committee. The first award was a non-qualified stock option to purchase 76,673 shares of common stock of the Company, granted on September 16, 2025. That award will terminate and never become exercisable unless Mr. te Boekhorst commences employment with the Company by November 30, 2025 at the latest. The second award (for up to an additional 85,000 shares, subject to adjustment) is to be made through a grant after commencement of employment and will consist of a mix of incentive stock options and non-qualified stock options. All of these stock options will carry a 10-year term from the date of grant. Each grant will vest in three equal increments, on the first, second, and third anniversaries of their respective dates of grant. The options granted September 16, 2025 have a stated exercise price of
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement):
This Press Release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans, goals and strategies for our business; the expected timing of key future events; future operational performance and financial results; future demand for our products; the timing and outcome of pending or anticipated applications for regulatory approvals; and any other statements that are not historical facts. Such statements involve known and unknown risks and uncertainties that may cause the Company’s actual results, financial or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
About ImmuCell:
ImmuCell Corporation’s (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, which provides Immediate Immunity™ to newborn dairy and beef calves, and is developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows that carries no FDA-required milk discard or pre-slaughter withdrawal label restrictions and that offers many potential benefits over traditional mastitis antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Michael F. Brigham, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| (207) 878-2770 | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| (602) 889-9700 | |
| iccc@lythampartners.com |
FAQ
Who is the new CEO of ImmuCell (NASDAQ:ICCC)?
What is Olivier te Boekhorst's background before joining ImmuCell?
What compensation package will ImmuCell's new CEO receive?
What will happen to ImmuCell's current CEO Michael Brigham?
When will Olivier te Boekhorst start as ImmuCell's CEO?
